Latest stories
Featured
Hikma expands its agreement with AFT Pharmaceuticals for the commercialisation of injectable pain medication Combogesic®...
Press Release, Business Development
12 February 2024
- Hikma signs exclusive licensing agreement with pharma& to bring innovative oncology treatment to MENA Press Release, Business Development 09 April 2025 Hikma signs exclusive licensing agreement with pharma& to bring innovative oncology treatment to MENA
- Hikma launches Cisatracurium Besylate Injection, USP in the US Press Release, Product 25 March 2025 Hikma launches Cisatracurium Besylate Injection, USP in the US
- Hikma announces Health Canada approval of KLOXXADO® (naloxone HCl) Nasal Spray 8 mg Press Release, Product 20 March 2025 Hikma announces Health Canada approval of KLOXXADO® (naloxone HCl) Nasal Spray 8 mg
- Developing our pipeline in growing therapeutic areas Story, Corporate 19 March 2025 Developing our pipeline in growing therapeutic areas
Related content